Teva Pharmaceutical Industries Limited (TEVA) Financials

TEVA Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 39.9 billion 32.1 billion
March 31, 2026 40.0 billion 31.8 billion
Dec. 31, 2025 40.7 billion 32.8 billion
Sept. 30, 2025 39.9 billion 32.6 billion

TEVA Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 307.0 million 40.0 million
March 31, 2026 -208.0 million 43.0 million
Dec. 31, 2025 1.0 billion 51.0 million
Sept. 30, 2025 233.0 million 34.0 million

TEVA Net Income

No data available :(

TEVA Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 3.7 billion 12.1 billion 282.0 million
March 31, 2026 3.7 billion 14.0 billion 280.0 million
Dec. 31, 2025 3.6 billion 15.3 billion 288.0 million
Sept. 30, 2025 2.2 billion 16.8 billion 283.0 million

TEVA Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 1.2 billion
March 31, 2026 1.2 billion
Dec. 31, 2025 1.2 billion
Sept. 30, 2025 1.2 billion

TEVA Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 104.0 million 250.0 million 1.0 billion 717.0 million
March 31, 2026 168.0 million 222.0 million 1.0 billion 696.0 million
Dec. 31, 2025 142.0 million 267.0 million 1.1 billion 753.0 million
Sept. 30, 2025 136.0 million 256.0 million 973.0 million 656.0 million

TEVA Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 4.1 billion 2.0 billion
March 31, 2026 4.0 billion 2.0 billion
Dec. 31, 2025 4.7 billion 2.1 billion
Sept. 30, 2025 4.5 billion 2.2 billion

TEVA Revenue by Segment
Graph available only for paid members. Upgrade to see it.

TEVA

Price: $41.10

52 week price:
18.83
41.10

Dividend Yield: 2.45%

Payout Ratio Range:
-300.00%
278.64%

Earnings Per Share: 0.60 USD

P/E Ratio: 57.43

Exchange: NYQ

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Country: Israel

Volume: 6.4 million

Ebitda: -12.5 billion

Market Capitalization: 46.0 billion

Links: